HSP90 and the chaperoning of cancer
The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [43]
In the citing paper
“This role as a potentiator for genetic variation has been observed in fungi as well as mammalian cancer cells20,88,135,136.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
In the citing paper
“Second, Hsp90 can enable the phenotypic effects of new mutations either by stabilizing mutant regulators or by stabilizing non-mutant regulators that mediate signalling required for adaptation.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
Citations
Cites
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“melanogaster and Arabidopsis thaliana model systems that HSP90 can conceal inherent genetic variation within populations of organism”
BackgroundSelf-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387 · cited 1×
“By contrast, in normal cells, there is a substantial pool of free HSP90 dimers that have low ATPase activity and low drug affinit”
BackgroundHsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048 · cited 1×
“Several detailed reviews are available that address the molecular and cellular biology of the heat-shock respons”
BackgroundThe 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“Drug binding at the N-terminus of HSP90 has now been shown to alter many of its normal function”
Background
Research works printed but not linked: 2
- McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
- Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
Cited by
Items 401–500 of 1,008
Ganetespib: research and clinical development
Modi, S., & Jhaveri, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s65804 · Cited by 92
“Ganetespib ([5-[2,4-Dihydroxy-5-(1-methylethyl)phenyl]-4- (1-methyl-1H-indol-5-yl)-2,4-dihydro-[1,2,4]triazol-3-one]) is a resorcinol-based, non-geldanamycin, synthetic small molecule second-generation HSP90 inhibitor (molecular weight = 364.4), similar to NYP-AUY922, AT-13387, and KW-2478.”
InfluentialShimomura, A., Yamamoto, N., Kondo, S., Fujiwara, Y., Suzuki, S., Yanagitani, N., Horiike, A., Kitazono, S., Ohyanagi, F., Doi, T., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0831 · Cited by 93
“tumor cells, resulting in potent, selective anticancer activity (1, 3, 5).”
BackgroundApoptotic Pathways in Tumor Progression and Therapy
Melet, A., Song, K., Bucur, O., Jagani, Z., Grassian, A. R., & Khosravi‐Far, R. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_4 · Cited by 99
Sevin, M., Girodon, F., Garrido, C., & de Thonel, A. (2015) · Mediators of Inflammation · doi:10.1155/2015/970242 · Cited by 100
Fionda, C., Soriani, A., Malgarini, G., Iannitto, M. L., Santoni, A., & Cippitelli, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901797 · Cited by 93
“emerged as attractive targets in cancer therapy (19).”
BackgroundInfluentialHSP90: Enabler of Cancer Adaptation
Jaeger, A. M., & Whitesell, L. J. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055533 · Cited by 99
“…et al. 1994) and radicicol (Schulte et al. 1998), a flurry of reports described the ability of these tool compounds to pharmacologically destabilize multiple signaling pathways simultaneously and kill cancer cells (Blagosklonny et al. 1996; Schulte et al. 1996, 1998; Whitesell & Lindquist 2005).”
BackgroundInfluentialSelf-citationDiscovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90
Barta, T. E., Veal, J. M., Rice, J. W., Partridge, J. M., Fadden, R. P., Ma, W., Jenks, M., Geng, L., Hanson, G. J., Huang, K. H., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.023 · Cited by 95
Hsp90: Friends, clients and natural foes
Verma, S., Goyal, S., Jamal, S., Singh, A. P., & Grover, A. (2016) · Biochimie · doi:10.1016/j.biochi.2016.05.018 · Cited by 99
Tsen, F., Bhatia, A., O'Brien, K., Cheng, C.-F., Chen, M., Hay, N., Stiles, B., Woodley, D. T., & Li, W. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00559-13 · Cited by 90
Global Functional Map of the p23 Molecular Chaperone Reveals an Extensive Cellular Network
Echtenkamp, F. J., Zelin, E., Oxelmark, E., Woo, J. I., Andrews, B. J., Garabedian, M., & Freeman, B. C. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.05.029 · Cited by 90
“Thus, Hsp90 has a central role in cell homeostasis, which is exemplified by its use as a therapeutic target for a variety of cancers and other diseases (Whitesell and Lindquist, 2005).”
Menezes, D. L., Taverna, P., Jensen, M. R., Abrams, T., Stuart, D., Yu, G. K., Duhl, D., Machajewski, T., Sellers, W. R., Pryer, N. K., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0667 · Cited by 87
“Hsp90 ensures the conformational and functional stability of multiple client proteins, including oncoproteins essential for tumor growth and survival (1, 2).”
BackgroundFranke, J., Eichner, S., Zeilinger, C., & Kirschning, A. (2013) · Natural Product Reports · doi:10.1039/c3np70012g · Cited by 100
To Fold or Not to Fold: Modulation and Consequences of Hsp90 Inhibition
Peterson, L. B., & Blagg, B. S. J. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.17 · Cited by 97
Sibinska, Z., Tian, X., Korfei, M., Kojonazarov, B., Kolb, J. S., Klepetko, W., Kosanovic, D., Wygrecka, M., Ghofrani, H. A., Weissmann, N., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01941-2015 · Cited by 85
Heat shock proteins in breast cancer progression–A suitable case for treatment?
Calderwood, S. K. (2010) · International Journal of Hyperthermia · doi:10.3109/02656736.2010.490254 · Cited by 90
“Hsp90 drugs have the advantage of multi-targeting, in that many of the oncogenic proteins depend on Hsp90 activity and a dynamic mechanism of inhibiting the evolution of treatment resistant cells [17, 18, 30].”
BackgroundStühmer, T., Zöllinger, A., Siegmund, D., Chatterjee, M., Grella, E., Knop, S. T., Kortüm, K. M., Unzicker, C., Jensen, M. R., Quadt, C., et al. (2008) · Leukemia · doi:10.1038/leu.2008.111 · Cited by 88
“3 of which a conspicuous number is involved in intracellular signalling cascades that promote proliferation andsor survival”
BackgroundZavareh, R. B., Spangenberg, S. H., Woods, A. C., Martínez‐Peña, F., & Lairson, L. L. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.10.005 · Cited by 92
Plasma HSP90AA1 Predicts the Risk of Breast Cancer Onset and Distant Metastasis
Liu, H., Zhang, Z., Huang, Y., Wei, W., Ning, S., Li, J., Liang, X.-Q., Liu, K., & Zhang, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.639596 · Cited by 101
“Therefore, HSP90 is considered an essential promoter of cancer cell survival, especially in breast cancer (Whitesell and Lindquist, 2005; Vartholomaiou et al., 2017).”
BackgroundAjiro, M., & Zheng, Z. (2015) · mBio · doi:10.1128/mbio.02068-14 · Cited by 99
“It has been known that overexpressed HSP90 in tumor cells promotes the stability of many oncoproteins, such as Her-2, Akt, Raf-1, Cdk4, Cdk6, and Src (27).”
BackgroundMethodInfluentialKurokawa, M., Zhao, C., Reya, T., & Kornbluth, S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00265-08 · Cited by 85
Profiles of Radioresistance Mechanisms in Prostate Cancer
Chaiswing, L., Weiss, H. L., Jayswal, R. D., Clair, D. K. S., & Kyprianou, N. (2018) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2018025946 · Cited by 94
Landriscina, M., Amoroso, M. R., Piscazzi, A., & Esposito, F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.078 · Cited by 87
“Thus, HSP90 has emerged as a promising target for the treatment of cancer [6].”
BackgroundWang, J., Cui, S., Zhang, X., Wu, Y., & Tang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062876 · Cited by 95
“The heat shock protein (HSP) 90 is an important molecular chaperone for protein folding, intracellular disposition and proteolytic turnover of key regulators of cell growth and survival [8].”
BackgroundBuchanan, G., Ricciardelli, C., Harris, J. M., Prescott, J., Yu, Z. C.-L., Li, J., Butler, L. M., Marshall, V. R., Scher, H. I., Gerald, W. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1646 · Cited by 91
“For example, cancer cells have a highly primed and sensitized Hsp90 chaperone system that allows more rapid responses to insult, buffers cellular signaling pathways against genetic instability, and enhances sensitivity to extracellular signaling ( 6 ).”
BackgroundBoridy, S., Le, P. U., Petrecca, K., & Maysinger, D. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.182 · Cited by 94
“The function of the 90-kDa HSP is to stabilize various oncogenic kinases and works in concert with proteasomal degradation to regulate protein stability.(44,45) We hypothesized that a broad-spectrum selective HSP90 inhibitor, like 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG), could act in concert with celastrol t…”
Noormohammadi, A., Khodakarami, A., Gutiérrez-García, R., Lee, H. J., Koyuncu, S., König, T., Schindler, C., Sáez, I., Fatima, A., Dieterich, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms13649 · Cited by 86
Fadden, P., Huang, K. H., Veal, J. M., Steed, P. M., Barabasz, A. F., Foley, B. E., Hu, M., Partridge, J. M., Rice, J. W., Scott, A., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.015 · Cited by 93
“Hsp90 has emerged as a promising drug target in as well as other diseases involving mutant, foreign, or aberrantly expressed proteins oncology (Whitesell and Lindquist, 2005; Chiosis et al., 2004; Calderwood et al., 2006; Neckers, 2007; Solit and Chiosis, 2008).”
BackgroundRazandi, M., Pedram, A., & Levin, E. R. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01354-09 · Cited by 89
“Hsp90 has been reported to chaperone nucleus-bound ER but repress its trans-activating activity in the absence of ligand (44).”
BackgroundHeat Shock Proteins as Danger Signals for Cancer Detection
Seigneuric, R., Mjahed, H., Gobbo, J., Joly, A.-L., Berthenet, K., Shirley, S., & Garrido, C. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00037 · Cited by 86
“Its expression in malignant cells is reported to be high and constitutive, suggesting a crucial role in survival and growth of cancer cells (Whitesell and Lindquist, 2005).”
BackgroundGiommarelli, C., Zuco, V., Favini, E., Pisano, C., Piaz, F. D., Tommasi, N. D., & Zunino, F. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0233-x · Cited by 85
“Indeed, heat shock proteins are often over-expressed in tumor cells, thus supporting their ability to survive under stressed conditions [9, 13].”
BackgroundHSP90 as a platform for the assembly of more effective cancer chemotherapy
Whitesell, L. J., & Lin, N. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.12.006 · Cited by 95
Self-citationZheng, Z., Zhang, X., Liu, X.-X., Jin, X., Dai, L., Cheng, H., Jing, D., Thu, P. M., Zhang, M., Li, H., et al. (2019) · Theranostics · doi:10.7150/thno.36505 · Cited by 90
“These two binding domains are closely related to cell proliferation and tumor progression [36].”
BackgroundInositol pyrophosphates: structure, enzymology and function
Barker, C. J., Illies, C., Gaboardi, G. C., & Berggren, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0115-2 · Cited by 92
“Some anticancer drugs are already known to target HSP90 leading to inhibition of its chaperone activity [133, 134].”
BackgroundTeng, Y., Ngoka, L. C. M., Mei, Y., Lesoon, L. A., & Cowell, J. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.335000 · Cited by 86
“Inhibition of HSP90 Leads to WASF3 Inactivation—HSP90 has a central position in the network of molecular chaperones that promote necessary protein folding and degradation (14).”
BackgroundGrover, A., Shandilya, A., Agrawal, V., Pratik, P., Bhasme, D., Bisaria, V. S., & Sundar, D. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-s1-s30 · Cited by 95
“The association of Hsp90 with a plethora of pathways including signal transduction, cell-cycle control, transcriptional regulation and many others [16-18] marks it as target for pharmacological modulation in a number of diseases, particularly for cancer, where the chaperoning of mutated and overexpressed oncoproteins…”
BackgroundDhamad, A. E., Zhou, Z., Zhou, J., & Du, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160312 · Cited by 94
“Because of its role in controlling SRs including ERs, and a separate role in protecting oncoproteins, Hsp90 inhibitors are in clinical trials for treating cancer [23, 24].”
BackgroundProtein Folding Sculpting Evolutionary Change
Lindquist, S. (2009) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2009.74.043 · Cited by 92
“understanding these evolutionary processes will help us guide new therapeutic strategies for cancer [8-10] and infectious disease [17, 18].”
BackgroundSelf-citationp23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity
Forafonov, F., Toogun, O. A., Grad, I., Suslova, E., Freeman, B. C., & Picard, D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02246-07 · Cited by 84
Lamoureux, F., Thomas, C., Yin, M.-J., Kuruma, H., Beraldi, E., Fazli, L., Zoubeidi, A., & Gleave, M. E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0994 · Cited by 84
“Chaperones act as genetic buffers stabilizing the phenotype of various cells and organisms at times of environmental stress, and enhance Darwinian fitness of cells during cancer progression and treatment resistance (13).”
Shen, S., Zhang, P., Lovchik, M. A., Li, Y., Tang, L.-Y., Chen, Z., Zeng, R., Ma, D., Yuan, J., & Yu, Q. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200810183 · Cited by 88
“A geldanamycin (GA) analogue, which inhibits Hsp90 by blocking its intrinsic ATPase activity, was the first in class inhibitor of Hsp90 in human clinical trials for cancer therapy.”
BackgroundInfluentialDiscovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90
Bussenius, J., Blazey, C. M., Aay, N., Anand, N. K., Arcalas, A., Baik, T., Bowles, O. J., Buhr, C. A., Costanzo, S., Curtis, J. K., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.07.052 · Cited by 84
The novel HSP90 inhibitor STA‐1474 exhibits biologic activity against osteosarcoma cell lines
McCleese, J. K., Bear, M. D., Fossey, S. L., Mihalek, R. M., Foley, K. P., Ying, W., Barsoum, J., & London, C. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24660 · Cited by 81
“Many HSP90 clients are recognized oncoproteins, notably EGFR family members, Akt, Bcr-Abl, mutant p53, Kit and Met.(19) Selectivity of HSP90 inhibitors for malignant versus normal cells is conferred by the fact that accumulation of over-expressed and mutated client proteins has been shown to promote a shift to the act…”
BackgroundInfluentialHsp90 and Client Protein Maturation
Wayne, N., Mishra, P., & Bolon, D. N. A. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-295-3_3 · Cited by 92
Lamoureux, F., Thomas, C., Yin, M.-J., Fazli, L., Zoubeidi, A., & Gleave, M. E. (2014) · European Urology · doi:10.1016/j.eururo.2013.12.019 · Cited by 83
Understanding ligand-based modulation of the Hsp90 molecular chaperone dynamics at atomic resolution
Colombo, G., Morra, G., Meli, M., & Verkhivker, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802879105 · Cited by 82
Kim, B., Kim, S., Jeong, S., Sohn, E. J., Jung, J. H., Lee, M. H., & Kim, S. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf302527p · Cited by 83
HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis
Ryu, H.-W., Shin, D.-H., Lee, D. H., Choi, J., Han, G., Lee, K. Y., & Kwon, S. H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.033 · Cited by 82
Matikas, A., Mistriotis, D., Georgoulias, V., & Kotsakis, A. P. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.12.005 · Cited by 88
Wang, L., Syn, N. L. X., Subhash, V. V., Any, Y., Thuya, W. L., Cheow, E. S. H., Kong, L. R., Yu, F., Peethala, P. C., Wong, A. L., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.030 · Cited by 83
Molecular Chaperones in Parkinson's Disease – Present and Future
Ebrahimi-Fakhari, D., Wahlster, L., & McLean, P. J. (2011) · Journal of Parkinson’s Disease · doi:10.3233/jpd-2011-11044 · Cited by 82
“ies (reviewed in [37, 39, 124, 125]).”
BackgroundTranscriptional Modulation of Heat-Shock Protein Gene Expression
Stephanou, A., & Latchman, D. S. (2010) · Biochemistry Research International · doi:10.1155/2011/238601 · Cited by 91
“Likewise, Hsps allow tumour cell survival, growth, and metastasis, even in growth factor-deprived conditions, by allowing continued protein translation and cellular proliferation [62, 63].”
BackgroundLee, J. H., Khadka, P., Baek, S. H., & Chung, I. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149831 · Cited by 96
Tian, Y., Wang, C., Chen, S., Liu, J., Fu, Y., & Luo, Y. (2019) · Journal of Cell Science · doi:10.1242/jcs.228213 · Cited by 79
“1C,D, lane 2). eHsp90α and clusterin synergistically promote tumor cell migration One major function of eHsp90α is to promote cell migration, involving the activation of ERK, AKT, NF-κB, and Src signaling pathways (Wong and Jay, 2016).”
BackgroundNatural heat shock protein 90 inhibitors in cancer and inflammation
Costa, T. E. M. M., Raghavendra, N. M., & Penido, C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112063 · Cited by 82
Cullin-RING Ligase 5: Functional characterization and its role in human cancers
Zhao, Y., Xiong, X., & Sun, Y. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.04.003 · Cited by 83
Mishra, S. J., Liu, W., Beebe, K. E., Banerjee, M., Kent, C. N., Munthali, V. Y., Koren, J., Taylor, J. A., Neckers, L. Μ., Holzbeierlein, J. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01700 · Cited by 85
Rise of the natural red pigment ‘prodigiosin’ as an immunomodulator in cancer
Anwar, M. M., Albanese, C., Hamdy, N. Μ., & Sultan, A. S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02815-4 · Cited by 84
“For example, prodigiosin inhibited HSP90 and rescued P53 in triple-negative breast cancer (TNBC) and P53-deficient CRC cells, respectively, inhibiting tumour growth and leading to tumour cell death [51, 59].”
BackgroundInfluentialCharacterisation of the Plasmodium falciparum Hsp70–Hsp90 organising protein (PfHop)
Gitau, G. W., Mandal, P., Blatch, G. L., Przyborski, J. M., & Shonhai, A. (2011) · Cell Stress and Chaperones · doi:10.1007/s12192-011-0299-x · Cited by 84
“This is particularly an important pathway to target, as inhibition of the Hsp70–Hsp90 pathway is known to lead to degradation of client proteins that depend on this pathway for folding (Whitesell and Lindquist 2005).”
BackgroundProia, D. A., Sang, J., He, S., Smith, D. L., Sequeira, M., Zhang, C., Liu, Y., Ye, S., Zhou, D., Blackman, R. K., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9790-6 · Cited by 82
“Heat shock protein 90 (Hsp90) is a molecular chaperone required for the post-translational stability and function of numerous key signal transduction proteins, termed ‘client’ proteins, many of which play critical roles in cell growth, differentiation and survival [9, 10].”
BackgroundYang, S., Qu, S., Perez-Tores, M., Sawai, A., Rosen, N., Solit, D. B., & Arteaga, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1042 · Cited by 80
“One mechanism that alleviates the conformational instability of oncogenic proteins is their association with the HSP90 chaperone (31, 42, 43).”
Chen, F., Pandey, D., Chadli, A., Catravas, J. D., Chen, T., & Fulton, D. J. R. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3669 · Cited by 81
“Inhibitors of Hsp90 have shown remarkable efficacy against various types of cancer (46), inflammation (6), cardiovascular disease (25), and acute lung injury (10).”
Lee, J. H., & Chung, I. K. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.08.026 · Cited by 81
Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis
Roh, S., Kasembeli, M. M., Bakthavatsalam, D., Chiu, W., & Tweardy, D. J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125975 · Cited by 87
“The sensitivity of a wide variety of tumors to inhibitors of HSP90 and HSP70 exemplifies the importance of molecular chaperones in maintaining survival of cancer cells [8,9].”
BackgroundCooperation of local motions in the Hsp90 molecular chaperone ATPase mechanism
Schulze, A., Beliu, G., Helmerich, D. A., Schubert, J., Pearl, L. H., Prodromou, C., & Neuweiler, H. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2111 · Cited by 85
“Engineered constructs for bacterial expression contained the genes of yeast Aha1, yeast Hsp82 in full-length, NTD (1-220) or NM-Domain (1-551) versions, with N-terminal His 6tag, cloned into a pRSET A vector (Invitrogen).”
MethodInfluentialTanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study
Richardson, P. G., Chanan‐Khan, A. A., Alsina, M., Albitar, M., Berman, D., Messina, M., Mitsiades, C. S., & Anderson, K. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08265.x · Cited by 80
“(Whitesell & Lindquist, 2005; Powers & Workman, 2006).”
Metabolism and Its Sequelae in Cancer Evolution and Therapy
Gillies, R. J., & Gatenby, R. A. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000102 · Cited by 85
“actions of cellular chaperones such as heat shock proteins, for example, HSP90 or GRPs.(5,6) Conversely, multiple genetic changes can give rise to common phenotypes, commonly referred to as “convergent evolution” or “functional equivalence.”
BackgroundVettoretti, G., Moroni, E., Sattin, S., Tao, J., Agard, D. A., Bernardi, A., & Colombo, G. (2016) · Scientific Reports · doi:10.1038/srep23830 · Cited by 82
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma
Mahipal, A., Tella, S. H., Kommalapati, A., Anaya, D., & Kim, R. D. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.003 · Cited by 80
Recent contributions of quinolines to antimalarial and anticancer drug discovery research
de Walle, T. V., Cools, L., Mangelinckx, S., & D’hooghe, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113865 · Cited by 86
Chu, B. W., Kovary, K. M., Guillaume, J., Chen, L., Teruel, M. N., & Wandless, T. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.499350 · Cited by 83
“We chose to characterize the behavior of 17-AAG, an Hsp90 inhibitor (49, 50), more in depth by treating cells for varying lengths of time before analysis by flow cytometry.”
BackgroundWhole chromosome aneuploidy: Big mutations drive adaptation by phenotypic leap
Chen, G., Rubinstein, B., & Li, R. (2012) · BioEssays · doi:10.1002/bies.201200069 · Cited by 79
“The possibility of targeting Hsp90 in tumor therapy has been actively investigated in recent years [71].”
BackgroundWeigel, B. J., Blaney, S. M., Reid, J. M., Safgren, S. L., Bagatell, R., Kersey, J., Neglia, J. P., Ivy, S. P., Ingle, A. M., Whitesell, L. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2270 · Cited by 80
Self-citationShaashua, L., Ben-Shmuel, A., Pevsner-Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., Barki, D., Nevo, R., Brown, L. E., Zhang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34081-3 · Cited by 79
HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance
Jhaveri, K. L., & Modi, S. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00015-4 · Cited by 84
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
Richardson, P. G., Badros, A. Z., Jagannath, S., Tarantolo, S., Wolf, J. L., Albitar, M., Berman, D., Messina, M., & Anderson, K. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08264.x · Cited by 77
“…heat, heavy metals, hypoxia and acidosis, and the subsequent overexpression of heat shock protein 90 (HSP90) are currently being explored, with cell stress response being particularly important for malignant cells stressed by chemotherapy (Takayama et al, 2003; Whitesell & Lindquist, 2005).”
BackgroundHeat Shock Protein 90 Inhibition in Lung Cancer
Shimamura, T., & Shapiro, G. I. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174ea3a · Cited by 88
The role of heat shock proteins in bladder cancer
Ischia, J. J., & So, A. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.108 · Cited by 85
Zou, M., Bhatia, A., Dong, H., Jayaprakash, P., Guo, J., Sahu, D., Hou, Y., Tsen, F., Tong, C., O'Brien, K., et al. (2016) · Oncogene · doi:10.1038/onc.2016.375 · Cited by 82
“Many of the client proteins are critical components of the cellular signaling pathways that regulate cell survival, metabolism and growth (5, 6, 7, 8).”
Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy
Sha, L., Wang, X., Li, J., Shi, X., Wu, L., Shen, Y., & Xu, Q. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160667 · Cited by 78
“Hsp90 is the most highly expressed cellular protein involved in the stabilization of other proteins and protein degradation under environmental stress (Whitesell and Lindquist, 2005).”
BackgroundTargeting chaperones in transformed systems – a focus on Hsp90 and cancer
Chiosis, G. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.1.37 · Cited by 79
“The intermediate complexes accumulate within the cell and recruit E3 ubiquitin ligases that drive the degradation of the client protein by the proteasome [6,8,10].”
BackgroundInfluentialThe activity of hsp90α promoter is regulated by NF-κB transcription factors
Ammirante, M., Rosati, A., Gentilella, A., Festa, M., Petrella, A., Marzullo, L., Pascale, M. C., Belisario, M. A., Leone, A., & Turco, M. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210716 · Cited by 78
“In neoplastic cells, this chaperone is implicated in cell protection against proapoptotic stimuli, originating from de-regulated proliferation or chemotherapeutic agents (Whitesell and Lindquist, 2005).”
BackgroundWan, R., Mo, Y., Chien, S., Li, Y., Li, Y., Tollerud, D. J., & Zhang, Q. (2011) · Nanotoxicology · doi:10.3109/17435390.2010.537791 · Cited by 79
Won, Y.-W., Yoon, S.-M., Sonn, C. H., Lee, K., & Kim, Y. (2011) · ACS Nano · doi:10.1021/nn200173u · Cited by 78
Proia, D. A., & Kaufmann, G. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0057 · Cited by 77
“As with other physiologic processes that may become co-opted by cancer cells, it has nowbecome apparent that the chaperoning functions of HSP90 can be subverted during tumorigenesis to facilitate malignant progression and maintain a transformed cellular phenotype (9).”
BackgroundTessarz, P., Schwarz, M., Mogk, A., & Bukau, B. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00201-09 · Cited by 78
“The concomitant involvement of members of the Hsp70 and Hsp90 chaperone families in stress-related, regulatory, and housekeeping functions allows the integration of environmental stimuli into regulatory networks (4, 24, 39, 40).”
BackgroundSymmetry broken and rebroken during the ATP hydrolysis cycle of the mitochondrial Hsp90 TRAP1
Elnatan, D., Betegon, M., Liu, Y., Ramelot, T., Kennedy, M. A., & Agard, D. A. (2017) · eLife · doi:10.7554/elife.25235 · Cited by 79
Multifaceted roles of HSF1 in cancer
Jiang, S., Tu, K., Fu, Q., Schmitt, D. C., Zhou, L., Lu, N., & Zhao, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-3674-x · Cited by 79
“The main function of HSPs is to aid in the process of normal protein folding and protect the proteome from the dangers of misfolding and aggregation [4].”
BackgroundQuantitative and Temporal Proteome Analysis of Butyrate-treated Colorectal Cancer Cells
Tan, H. T., Tan, S., Lin, Q., Lim, T. K., Hew, C. L., & Chung, M. C. M. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700483-mcp200 · Cited by 84
“tumors (46, 47) and was detected to be up-regulated in trans-”
BackgroundMediani, L., Antoniani, F., Galli, V., Vinet, J., Carrà, A. D., Bigi, I., Tripathy, V., Tiago, T., Cimino, M., Leo, G., et al. (2021) · EMBO reports · doi:10.15252/embr.202051740 · Cited by 78
“Conversely, Hsp90 is highly expressed in a large variety of cancers, where it plays complex roles that ultimately promote cancer cell proliferation and inhibition of Hsp90 has been shown to interfere with tumorigenesis (Whitesell & Lindquist, 2005; Calderwood & Neckers, 2016; Rodina et al, 2016).”
Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer
Wang, L., Zhang, Q., & You, Q. (2021) · Medicinal Research Reviews · doi:10.1002/med.21807 · Cited by 83
“protect themselves from oncoprotein mutation and overexpression and to avoid misfolded conformations and degradation.(11,13) Therefore, HSP90 has long been regarded as a potential anticancer target for its crucial roles in oncogene addiction and cancer cell survival.”
BackgroundThe Cytosolic Chaperonin CCT/TRiC and Cancer Cell Proliferation
Benmammar, C., Cresteil, T., & Melki, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060895 · Cited by 77
“They promote tumour cell survival, growth and metastasis, even in growth factor deprived conditions, by allowing continued protein translation and cellular proliferation [7].”
BackgroundFour-colour FRET reveals directionality in the Hsp90 multicomponent machinery
Ratzke, C., Hellenkamp, B., & Hugel, T. (2014) · Nature Communications · doi:10.1038/ncomms5192 · Cited by 87
Heat shock proteins as novel therapeutic targets in cancer.
Soo, E. T., Yip, G. W., Lwin, Z. M., Kumar, S. D., & Bay, B. (2008) · PubMed · Cited by 85
Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
Li, T., Jiang, H., Tong, Y., & Lu, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0602-8 · Cited by 80
“Various studies in recent years have helped determine how Cdc37 enables Hsp90 chaperone machinery to recognize specific client proteins progressively; however, the full-length structures of client protein with either Hsp90 or Cdc37 remain to be elucidated [1, 2, 27, 45].”
BackgroundLee, K., Thwin, A. C., Nadel, C. M., Tse, E., Gates, S. N., Gestwicki, J. E., & Southworth, D. R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.023 · Cited by 76
The Hsp90 chaperone machinery: from structure to drug development
Hahn, J. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.10.623 · Cited by 82
Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance
Zhang, J., Li, H., Liu, Y., Zhao, K., Wei, S., Sugarman, E. T., Liu, L., & Zhang, G. (2022) · Cells · doi:10.3390/cells11182778 · Cited by 81
“Therefore, they have been actively pursued as therapeutic targets for cancer treatment [12].”
BackgroundZhou, D., Liu, Y., Ye, J., Ying, W., Ogawa, L. S., Inoue, T., Tatsuta, N., Wada, Y., Koya, K., Huang, Q. M., et al. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.09.018 · Cited by 78
“In this setting Hsp90 can serve as a biochemical buffer to promote the structural and functional stability of a number of oncogenic signaling proteins causally implicated in human cancers (Trepel et al., 2010; Whitesell and Lindquist, 2005).”
BackgroundKlaić, L., Morimoto, R. I., & Silverman, R. B. (2012) · ACS Chemical Biology · doi:10.1021/cb200539u · Cited by 79
Smyd3-associated regulatory pathways in cancer
Giakountis, A., Moulos, P., Sarris, M. E., Hatzis, P., & Talianidis, I. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.008 · Cited by 86
Metadata
- Authors
- Whitesell, L., & Lindquist, S. L.
- Affiliations
- University of Arizona (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Whitesell, Luke
- ORCID
- Whitesell, Luke
- Venue
- Nature Reviews Cancer
- Published
- 2005-09-20
- Volume
- 5
- Issue
- 10
- Pages
- 761-772
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2022531767
- Cited by
- 2,502
- References
- 149
- Citations by year
- 2026: 81 · 2025: 87 · 2024: 83 · 2023: 97 · 2022: 90 · 2021: 113 · 2020: 123 · 2019: 142 · 2018: 99 · 2017: 116 · 2016: 126 · 2015: 152 · 2014: 154 · 2013: 153 · 2012: 167
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HSP90, molecular chaperones, carcinogenesis, malignant transformation, somatic evolution, protein folding, proteome, anticancer drug targets, chaperone inhibition
- MeSH terms
- Animals, Humans, Neoplasms, Molecular Chaperones, HSP90 Heat-Shock Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.